Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Propranolol, a pleiotropic β-adrenergic blocker, has been anecdotally reported to reduce cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been rigorously evaluated in animal models, nor has its mechanism of action in CCM been defined. We report that propranolol or its...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Li, Wenqing, Shenkar, Robert, Detter, Mathew R., Moore, Thomas, Benavides, Christian, Lightle, Rhonda, Girard, Romuald, Hobson, Nicholas, Cao, Ying, Li, Yan, Griffin, Erin, Gallione, Carol, Zabramski, Joseph M., Ginsberg, Mark H., Marchuk, Douglas A., Awad, Issam A.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2021
Matèries:
Concise Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843213/
https://ncbi.nlm.nih.gov/pubmed/33301422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI144893
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars